Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33. doi:10.3322/caac.2165433433946
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi:10.3322/caac.2166033538338
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Feng RM, Zong YN, Cao SM, Xu RH. Current cancer situation in China: good or bad news from the 2018 global cancer statistics? Cancer Commun. 2019;39:22. doi:10.1186/s40880-019-0368-6
   PubMed Web of Science ®Google Scholar
• Reck M, Rabe KF. Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med. 2017;377:849–861. doi:10.1056/NEJMra170341328854088
   PubMed Web of Science ®Google Scholar
• Hsu WH, Yang JC, Mok TS, Loong HH. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol. 2018;29:i3–i9. doi:10.1093/annonc/mdx70229462253
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Non-small cell lung cancer version 5; 2021. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed June 15, 2021.
   Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–2388. doi:10.1056/NEJMoa090953020573926
   PubMed Web of Science ®Google Scholar
• Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:5892–5899. doi:10.1200/JCO.2005.02.84016043829
   PubMed Web of Science ®Google Scholar
• Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2. J Clin Oncol. 2004;22:785–794. doi:10.1200/JCO.2004.07.21514990633
   PubMed Web of Science ®Google Scholar
• Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1. J Clin Oncol. 2004;22:777–784. doi:10.1200/JCO.2004.08.00114990632
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007;25:1545–1552. doi:10.1200/JCO.2005.05.147417442998
   PubMed Web of Science ®Google Scholar
• Hosomi Y, Morita S, Sugawara S, et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol. 2020;38:115–123. doi:10.1200/JCO.19.0148831682542
   PubMed Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113–125. doi:10.1056/NEJMoa171313729151359
   PubMed Web of Science ®Google Scholar
• Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9:235–251. doi:10.1002/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O10790702
   PubMed Web of Science ®Google Scholar
• Diaby V, Adunlin G, Montero AJ. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics. 2014;32:101–108. doi:10.1007/s40273-013-0123-924338265
   PubMed Web of Science ®Google Scholar
• Liu M, Zhang L, Huang Q, Li N, Zheng B, Cai H. Cost-effectiveness analysis of ceritinib and alectinib versus crizotinib in the treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer. Cancer Manag Res. 2019;11:9195–9202. doi:10.2147/CMAR.S22344131749634
   PubMed Web of Science ®Google Scholar
• National Bureau of Statistics. National data of National Bureau of Statistics in 2020. Available from: https://data.stats.gov.cn/tablequery.htm?code=AD02. Accessed October 28, 2021.
   Google Scholar
• Nafees B, Lloyd AJ, Dewilde S, Rajan N, Lorenzo M. Health state utilities in non-small cell lung cancer: an international study. Asia Pac J Clin Oncol. 2017;13:e195–e203. doi:10.1111/ajco.1247726990789
   PubMed Web of Science ®Google Scholar
• Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6:84. doi:10.1186/1477-7525-6-8418939982
   PubMed Web of Science ®Google Scholar
• You R, Liu J, Wu DB, et al. Cost-effectiveness analysis of EGFR mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in China. Cancer Manag Res. 2019;11:10239–10248. doi:10.2147/CMAR.S21972231824194
   PubMed Web of Science ®Google Scholar
• Kim Y, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Efficacy and safety of afatinib for EGFR-mutant non-small cell lung cancer, compared with gefitinib or erlotinib. Cancer Res Treat. 2019;51:502–509. doi:10.4143/crt.2018.11729898592
   PubMed Web of Science ®Google Scholar
• Yang JJ, Zhou Q, Yan HH, et al. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br J Cancer. 2017;116:568–574. doi:10.1038/bjc.2016.45628103612
   PubMed Web of Science ®Google Scholar
• Rossi A, La Salvia A, Di Maio M. Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer. Expert Rev Respir Med. 2017;11:171–180. doi:10.1080/17476348.2017.129052628152323
   PubMed Web of Science ®Google Scholar
• Noronha V, Patil VM, Joshi A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol. 2020;38:124–136. doi:10.1200/JCO.19.0115431411950
   PubMed Web of Science ®Google Scholar
• Zhao Q, Sun K, Lei X, Cai L. A meta-analysis of the therapeutic effect of gefitinib combined with chemotherapy and chemotherapy alone in treating non-small cell lung cancer. Medicine. 2020;99:e21490. doi:10.1097/MD.000000000002149032756179
   PubMed Web of Science ®Google Scholar
• Narita Y, Matsushima Y, Shiroiwa T, et al. Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer. Lung Cancer. 2015;90:71–77. doi:10.1016/j.lungcan.2015.07.00626259876
   PubMed Web of Science ®Google Scholar
• Kimura M, Yasue F, Usami E, et al. Cost-effectiveness and safety of the molecular targeted drugs Afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Mol Clin Oncol. 2018;9:201–206.30101022
   PubMed Web of Science ®Google Scholar
• Cai H, Zhang L, Li N, et al. Cost-effectiveness of osimertinib as first-line treatment and sequential therapy for EGFR mutation-positive non-small cell lung cancer in China. Clin Ther. 2019;41:280–290. doi:10.1016/j.clinthera.2018.12.00730639208
   PubMed Web of Science ®Google Scholar
• Svaton M, Bratova M, Fischer O, et al. Real-life effectiveness of afatinib versus gefitinib in patients with non-small-cell lung cancer: a Czech multicentre study. Anticancer Res. 2021;41:2059–2065. doi:10.21873/anticanres.1497533813414
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-lung 7 trial. Ann Oncol. 2017;28:270–277. doi:10.1093/annonc/mdw61128426106
   PubMed Web of Science ®Google Scholar
• Li WQ, Li LY, Chai J, Cui JW. Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients. Cancer Med. 2021;10:1964–1974. doi:10.1002/cam4.373333626238
   PubMed Web of Science ®Google Scholar